Blindrafélagið - Samtök blindra og sjónskertra á Íslandi - Fræðslu og vísindagreinar

Fræðslubæklingar á íslensku um augnsjúkdóma

Thu, 26 Jan 2012 13:06:00 +0000

Hér má sjá fræðslubæklinga á íslensku um aldurstengda augnbotnahrörnun (AMD), gláku og Retinitis Pigmentosa (RP)

First patient receives novel gene therapy for choroideraemia type, a of blindness

Mon, 28 Nov 2011 14:13:00 +0000

The first patient to receive gene therapy for an incurable type of blindness was treated at the John Radcliffe Hospital end of October 2011 in Oxford this week as part of a trial led the University of Oxford.

Fyrstu tilraunirnar með mennskar stofnfrumur heimilaðar

Thu, 22 Sep 2011 16:21:00 +0000

Bandaríska fyrirtækið ACT hefur fengið leyfi breskra yfirvalda til að hefja meðferð sjúklinga fyrir Stargard sjúkdómnum með notkun mennskra stofnfruma. Hér fyrir neðan má lesa frétt af vef bresku RP samtakanna um málið..

Longitudinal Study of Cone Photoreceptors duringRetinal Degeneration and in Response to CiliaryNeurotrophic Factor Treatment

Thu, 16 Jun 2011 15:29:00 +0000

PURPOSE. To study cone photoreceptor structure and function in patients with inherited retinal degenerations treated with sustained-release ciliary neurotrophic factor (CNTF).

Ciliary neurotrophic factor delivered by encapsulatedcell intraocular implants for treatment of geographicatrophy in age-related macular degeneration

Thu, 16 Jun 2011 15:10:00 +0000

There is no treatment available for vision loss associated with advanced dry age-related macular degeneration (AMD) or geographic atrophy (GA). In a pilot, proof of concept phase 2 study, we evaluated ciliary neurotrophic factor (CNTF) delivered via an intraocular encapsulated cell technology implant for the treatment of GA.

Major reviw - Adult Refsum Disease: A Form of TapetoretinalDystrophy Accessible to Therapy

Fri, 26 Nov 2010 13:31:00 +0000

Abstract. Adult Refsum disease is characterized by an elevated plasma phytanic acid level and high
concentrations of phytanic acid in a variety of tissues. Besides tapetoretinal degeneration, additional
symptoms are anosmia, skeletal malformations, chronic polyneuropathy, cerebellar ataxia, sensorineural
hearing loss, ichthyosis, and cardiac abnormalities. A diet low in phytanic acid ameliorates
polyneuropathy and ataxia and slows or even stops the other manifestations. In order to be able to
apply dietary therapy, as many patients as possible (even better if all of them are) have to be identified
at an early stage. The ophthalmologist plays a crucial role in achieving this goal because of the early
manifestation of the tapetoretinal degeneration. (Surv Ophthalmol 55:531--538, 2010. ! 2010
Elsevier Inc. All rights reserved.)

ReVision's Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase

Tue, 21 Sep 2010 15:09:00 +0000

2b Trial - Drugs.com MedNews. Data Presented at Annual Meeting of the American Society of Retinal Specialists Results Show Fenretinide's Dual Mechanisms of Action May Have Clinical Benefit in GA and Prevent CNV

Piecing Together the Complex AMD Puzzle

Sat, 28 Aug 2010 14:48:00 +0000

Grein af vef Foundation Fighting Blindness USA

RP fyrirlestrar á NOK2010

Wed, 11 Aug 2010 14:21:00 +0000

Hér er hægt að hlusta á 3 af aðgengilegustu fyrirlestrunum um arfgenga sjónhimnusjúkdóma og tilraunir til að finna við þeim meðferðir,sem fluttir voru á norræna augnlæknaþinginu, en þingið fór fram í Reykjavík 4 - 7 ágúst 2010.

Latest results of the 16th Retina International Worldconference 2010 - Stresa, Italy

Wed, 28 Jul 2010 15:57:00 +0000

Abstracts in english

Árangur tveggja áratuga rannsókna á sjónhimnusjúkdómum. (Retina Disorder RD) 1990-2010

Fri, 23 Jul 2010 18:22:00 +0000

Úr myrkri vanþekkingar til vísindarannsókna og inn í ljós klínískrar tilrauna -

Samantektar fyrirlestur á alheimsráðstefnu Retina International í Stresa á Ítalíu 26 & 27 júní 2010

Practice Perspectives

Mon, 19 Jul 2010 09:54:00 +0000

How many times in the last week have you heard the terms, "accountability," "documentation," "measurement," "evidence," "goals," or "objectives"? In both education and rehabilitation, our work increasingly follows a precise model of planning, instruction, and evaluation to verify effectiveness.

Retina International Reports from the ARVO 2010 Annual Meeting

Mon, 21 Jun 2010 11:26:00 +0000

This series of reports is based on presentations by scientists and scientist/clinicians at the ARVO 2010 Annual Meeting (“The Future of Eye and Vision Research”), in Ft. Lauderdale, Florida, held from May 2 – 6, 2010. There were uncountable numbers of opportunities to glean new information about retinal degenerative diseases and to learn about new devices and approaches for detecting and treating each.

Canadian-led study holds promise for patients living with a progressive form of blindness

Mon, 7 Jun 2010 15:24:00 +0000

TORONTO, May 26 /CNW/ - A new study led by Dr. Robert Koenekoop at the Montreal Children's Hospital at the McGill University Health Centre holds promise for certain patients with Leber congenital amaurosis (LCA), an inherited retinal degenerative disease that causes significant vision loss from birth.Útdráttur

Viðtal við Dr. Gerald Chader um RP

Thu, 1 Apr 2010 17:08:00 +0000

Hér má sjá viðtal við Dr. Gerald Chader sem er einn virtasti vísindamaður heims sem fæst við rannsóknir á augnsjúkdómnum RP eða Retinitis Pigmentosa.

Verðlauna fræðslumyndbönd um AMD

Thu, 1 Apr 2010 13:26:00 +0000

Niðurstaða fengin í samkeppni AMD Alliance International um gerð fræðslumyndbands um AMD (ellihrörnun í augnbotnum).

Subretinal Implant Restores Unprecedented Level of Vision to Blind Patients

Mon, 22 Mar 2010 13:34:00 +0000

REUTLINGEN, Germany--(BUSINESS WIRE)--Retina Implant, AG, a leading developer of subretinal implants for the visually impaired, today announced scientific revelations discovered during the company's first human clinical trial. The results achieved in the 11 patients that were involved in the trial exceeded the company's expectations for their first trial.

Researchers Develop New Tool for Gene Delivery

Fri, 29 Jan 2010 09:25:00 +0000

Researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts have developed a new tool for gene therapy that significantly increases gene delivery to cells in the retina compared to other carriers and DNA alone, according to a study published in the January issue of The Journal of Gene Medicine.

Nýjar stofnfrumurannsóknir geta hjálpað blindum

Tue, 5 Jan 2010 14:02:00 +0000

Hér fer þýðing á grein úr tímariti norsku blindrasamtakanna „Norges blinde“ frá 17.desember 2009 eftir Ingunn Saltbones Leini

Blind patients in Manchester join global trial of 'bionic eye'

Tue, 16 Jun 2009 11:34:00 +0000

Eye surgeons at Manchester Royal Eye Hospital have implanted an intraocular electronic retinal prosthesis or 'bionic eye' in two Manchester patients who became blind due to advanced retinitis pigmentosa – an inherited and degenerative disease of the retina.

Retinal Disease: Progress Reports from the Twelfth Annual Vision Conference and the ARVO 2009 Annual MeetingTitill

Sat, 30 May 2009 17:34:00 +0000

The reports below were prepared exclusively for Retina International. They are based on presentations made by scientists and clinicians at the Twelfth Annual Vision Conference (“Mechanisms of Macular Degeneration”) and the ARVO 2009 Annual Meeting, in Ft. Lauderdale, Florida, held consecutively from May 1 – 7, 2009.

Results from Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors

Fri, 29 May 2009 17:50:00 +0000

Fréttatilkynning frá bandaríska fyrirtækinu Neurotech þar sem greint er frá fyrstu niðurstöðum í klínískum lyfjatilraunum við að finna meðferð við Retinitis Pigmentosa (RP)

Second Sight útvíkkar alþjóðlega klíniskar prófanir á rafeindasjónarbúnaðinum Argus II

Mon, 12 Jan 2009 10:23:00 +0000

Second Sight® Medical Products, Inc., sem er leiðandi fyrirtæki í þróun á rafeindasjón fyrir blinda, hefur tilkynnt að það ætli að auka við fjölda þeirra einstaklinga sem taka þátt í prófunum á ArgusTM II, rafeindasjónbúnaðinum, í tilraunarstöðvum fyrirtækisins í Evrópu.

Minutes of the 2009 Meeting of the Scientific and Medical Advisory Board of Retina International

Thu, 28 May 2009 14:08:00 +0000

Fundargerð Vísinda og ráðgjafarnefndar Retina International, sem haldinn var mánudaginn 4 maí, á ársfundi AVRO í Fort Lauderdale í Bandaríkjunum.

$2.4 million to develop stem cell therapies to reverse blindness Canada’s leading researchers working together thanks to unique grant

Thu, 5 Mar 2009 10:22:00 +0000

March 4, 2009 – Leading vision researchers from across Canada are embarking on a five-year, $2.4 million collaborative project to develop stem cell therapies to reverse blindness. Canada’s largest private charity for vision research, the Foundation Fighting Blindness, is partnering with the Canadian Institutes of Health Research to fund the program. The research team includes seven principal scientists led by Dr. Valerie Wallace, Senior Scientist at the Ottawa Health Research Institute (the research arm of The Ottawa Hospital) and Associate Professor at the University of Ottawa.

Byltingakenndar tilraunir á sjúklingum á sviði augnvísinda fá grænt ljós

Mon, 2 Feb 2009 11:47:00 +0000

Bandaríska fyrirtækið Neurotech hefur fengið leyfi bandarískra yfirvalda (FDA) fyrir byltingakenndum tilraunir á sjúklingum til meðferðar á RP og ellihrörnun í augnbotnum (Dry AMD).